Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195476 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL1194794 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL1194792 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL1195228 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL1195226 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL20999337 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MCL1MCHR1KMT2AMEN1 | |
| SCHEMBL1195259 | 0.79 | NPSR1 (0.62) | KMT2AMEN1MAPTHTT | |
| SCHEMBL1195260 | 0.79 | NPSR1 (0.62) | KMT2AMEN1MAPTHTT | |
| SCHEMBL15346324 | 0.78 | KMT2A (0.61) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL9536115 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2011-02-03 | — | — | US | claimed |
| US-8841347-B2 | Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use | UNIWERSYTET JAGIELLONSKI (PL) | 2014-09-23 | — | — | US | disclosed |
| US-8633251-B2 | Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use | UNIWERSYTET JAGIELLONSKI (PL) | 2014-01-21 | — | — | US | disclosed |
| US-20130289118-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2013-10-31 | — | — | US | disclosed |
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289118-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | SCN1A, SCN3A, ACHE | ALDH1A1 461/4885MCL1 2481/4885MCHR1 4150/4885 |
| US-20110028562-A1 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE | ACHE, CNR2, SCN1A | ALDH1A1 541/4885MCL1 2532/4885MCHR1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.